(4aS)-5-[(2,4-diaminopteridin-6-yl)methyl]-4a,5-dihydro-2H-dibenzo[b,f]azepin-8-ol

This compound is a synthetic small molecule belonging to the benzazepine class and features both a dibenzoazepine core and a pteridine moiety[1][7]. It is known as Q22 in structural biology databases and has been studied primarily as an experimental inhibitor of dihydrofolate reductase (DHFR), an enzyme critical for DNA synthesis and cell proliferation[9][10]. The compound acts by binding to DHFR—similar to methotrexate—and thereby blocks folate metabolism pathways essential for nucleotide biosynthesis. Its primary use has been in biochemical research as a potent and selective DHFR inhibitor; it is not approved for clinical use or marketed under any brand name[1][7][10].

Other names

(1S)-2-[(2,4-diaminopteridin-6-yl)methyl]-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-3,5,7,9,11,14-hexaen-6-ol(4aS)-5-(2,4-diamino-pteridinylmethyl)-4a,5-dihydro-dibenzo[b,f]azepin 8 ol2H-Dibenz[b,f]azepin 8 ol 5 [(2,4 diamino 6 pteridinyl)methyl] 4a 5 dihydro (4aS)